Optimizing treatment for metastatic renal cell carcinoma

References

• Ljungberg B, Campbell SC, Cho HY et al. The epidemiology of renal cell carcinoma. Eur. Urol.60(4), 615–621 (2011).
   PubMed Web of Science ®Google Scholar
• Flanigan RC, Campbell SC, Clark JI, Picken MM. Metastatic renal cell carcinoma. Curr. Treat. Options Oncol.4(5), 385–390 (2003).
   PubMedGoogle Scholar
• Skolarikos A, Alivizatos G, Laguna P, de la Rosette J. A review on follow-up strategies for renal cell carcinoma after nephrectomy. Eur. Urol.51(6), 1490–1500; discussion 1501 (2007).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J. Clin. Oncol.20(1), 289–296 (2002).
   PubMed Web of Science ®Google Scholar
• Patil S, Ishill N, Deluca J, Motzer RJ. Stage migration and increasing proportion of favorable-prognosis metastatic renal cell carcinoma patients: implications for clinical trial design and interpretation. Cancer116(2), 347–354 (2010).
   PubMedGoogle Scholar
• Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst. Rev.1, CD001425 (2005).
   PubMed Web of Science ®Google Scholar
• Negrier S, Perol D, Ravaud A et al. Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial. Cancer110(11), 2468–2477 (2007).
   PubMed Web of Science ®Google Scholar
• Medical Research Council Renal Cancer Collaborators. Interferon-[alpha] and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet353(9146), 14–17 (1999).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J. Clin. Oncol.27(22), 3584–3590 (2009).
   PubMed Web of Science ®Google Scholar
• Escudier B, Bellmunt J, Negrier S et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J. Clin. Oncol.28(13), 2144–2150 (2010).
   PubMed Web of Science ®Google Scholar
• Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med.356(22), 2271–2281 (2007).
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, White DE, Steinberg SM. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann. Surg.228(3), 307–319 (1998).
   PubMed Web of Science ®Google Scholar
• Escudier B, Kataja V. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol.21(Suppl. 5), v137–v139 (2010).
   PubMed Web of Science ®Google Scholar
• Chow WH, Dong LM, Devesa SS. Epidemiology and risk factors for kidney cancer. Nat. Rev. Urol.7(5), 245–257 (2010).
   PubMed Web of Science ®Google Scholar
• Wiesener MS, Munchenhagen PM, Berger I et al. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas. Cancer Res.61(13), 5215–5222 (2001).
   PubMed Web of Science ®Google Scholar
• George DJ, Kaelin WG Jr. The von Hippel–Lindau protein, vascular endothelial growth factor, and kidney cancer. N. Engl. J. Med.349(5), 419–421 (2003).
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Davis ID, Mardiak J et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized Phase III trial. J. Clin. Oncol.28(6), 1061–1068 (2010).
   PubMed Web of Science ®Google Scholar
• Rini BI, Halabi S, Rosenberg JE et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J. Clin. Oncol.28(13), 2137–2143 (2010).
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Hawkins RE, Szczylik C et al. Phase III trial of pazopanib in advanced renal cell carcinoma: final overall survival results. Ann. Oncol.21(Suppl. 8), viii10 (2010).
   Google Scholar
• Porta C, Szczylik C. Tolerability of first-line therapy for metastatic renal cell carcinoma. Cancer Treat. Rev.35(3), 297–307 (2009).
   PubMed Web of Science ®Google Scholar
• Hutson TE, Figlin RA, Kuhn JG, Motzer RJ. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist13(10), 1084–1096 (2008).
   PubMed Web of Science ®Google Scholar
• Schmidinger M, Bellmunt J. Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma. Cancer Treat. Rev.36(5), 416–424 (2010).
   PubMed Web of Science ®Google Scholar
• van der Veldt AA, Boven E, Helgason HH et al. Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer. Br. J. Cancer99(2), 259–265 (2008).
   PubMed Web of Science ®Google Scholar
• Ather MH, Masood N, Siddiqui T. Current management of advanced and metastatic renal cell carcinoma. Urol. J.7(1), 1–9 (2010).
   PubMed Web of Science ®Google Scholar
• Thomas AA, Rini BI, Stephenson AJ et al. Surgical resection of renal cell carcinoma after targeted therapy. J. Urol.182(3), 881–886 (2009).
   PubMed Web of Science ®Google Scholar
• Jonasch E, Wood CG, Matin SF et al. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J. Clin. Oncol.27(25), 4076–4081 (2009).
   PubMed Web of Science ®Google Scholar
• Mills EJ, Rachlis B, O’Regan C, Thabane L, Perri D. Metastatic renal cell cancer treatments: an indirect comparison meta-analysis. BMC Cancer9, 34 (2009).
   PubMed Web of Science ®Google Scholar
• Escudier B, Szczylik C, Hutson TE et al. Randomized Phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma. J. Clin. Oncol.27(8), 1280–1289 (2009).
   PubMed Web of Science ®Google Scholar
• McCann L, Amit O, Pandite L, Amado R. An indirect comparison analysis of pazopanib versus other agents in metastatic renal cell carcinoma (mRCC). J. Clin. Oncol.28, (2010) (Abstract e15128).
   Google Scholar
• Markman M. The dangers of ‘cross-trial’ and ‘cross-retrospective experience’ comparisons: examples employing data in the peer-reviewed ovarian cancer literature. Cancer109(10), 1929–1932 (2007).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med.356(2), 115–124 (2007).
   PubMed Web of Science ®Google Scholar
• Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol.23(5), 1011–1027 (2005).
   PubMed Web of Science ®Google Scholar
• Kumar R, Crouthamel MC, Rominger DH et al. Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. Br. J. Cancer101(10), 1717–1723 (2009).
   PubMed Web of Science ®Google Scholar
• Sonpavde G, Hutson TE. Pazopanib: a novel multitargeted tyrosine kinase inhibitor. Curr. Oncol. Rep.9(2), 115–119 (2007).
   PubMedGoogle Scholar
• Karaman MW, Herrgard S, Treiber DK et al. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol.26(1), 127–132 (2008).
   PubMed Web of Science ®Google Scholar
• Lyman SD, Jacobsen SE. c-kit ligand and Flt3 ligand: stem/progenitor cell factors with overlapping yet distinct activities. Blood91(4), 1101–1134 (1998).
   PubMed Web of Science ®Google Scholar
• Montoya L. Managing hematologic toxicities in the oncology patient. J. Infus. Nurs.30(3), 168–172 (2007).
   PubMedGoogle Scholar
• Hu-Lowe DD, Zou HY, Grazzini ML et al. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin. Cancer Res.14(22), 7272–7283 (2008).
   PubMed Web of Science ®Google Scholar
• Flanigan RC, Salmon SE, Blumenstein BA et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N. Engl. J. Med.345(23), 1655–1659 (2001).
   PubMed Web of Science ®Google Scholar
• Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet358(9286), 966–970 (2001).
   PubMed Web of Science ®Google Scholar
• Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind Phase III trial. Lancet370(9605), 2103–2111 (2007).
   PubMed Web of Science ®Google Scholar
• Rini BI, Halabi S, Rosenberg JE et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J. Clin. Oncol.26(33), 5422–5428 (2008).
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the Phase III treatment approaches in renal cancer global evaluation trial. J. Clin. Oncol.27(20), 3312–3318 (2009).
   PubMed Web of Science ®Google Scholar
• Amin C, Wallen E, Pruthi RS, Calvo BF, Godley PA, Rathmell WK. Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy. Urology72(4), 864–868 (2008).
   PubMed Web of Science ®Google Scholar
• Cowey CL, Amin C, Pruthi RS et al. Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma. J. Clin. Oncol.28(9), 1502–1507 (2010).
   PubMed Web of Science ®Google Scholar